Future of BCG in NMIBC

Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the future of first-line treatment be a noninfectious agent that would be easier to develop and include more data.

EP: 1.Standard of Care in NMIBC

EP: 2.BCG-Unresponsive NMIBC and Treatments

EP: 3.Recent FDA Approvals in NMIBC

EP: 4.Selecting Treatment for BCG-Unresponsive NMIBC

EP: 5.BOND-003 Trial and Cretostimogene for Treatment of NMIBC

EP: 6.Other Emerging Intravesical Therapies in NMIBC

EP: 7.Emerging Immunotherapies in NMIBC

Now Viewing

EP: 8.Future of BCG in NMIBC

Video content above is prompted by the following:

• Given these recent advances and emerging agents, do you think BCG monotherapy will remain the first-line treatment for intermediate-risk and high-risk disease?

Related Videos

Related Content

Advertisement

February 19th 2025

FDA approves expanded access program to provide alternative source of BCG

Hannah Clarke

According to ImmunityBio, shipments of rBCG are set to begin immediately via the EAP.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

February 17th 2025

Anktiva under review in UK for BCG-unresponsive NMIBC with CIS

Hannah Clarke

Anktiva is also currently under review for the CIS indication in the EU.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

February 15th 2025

Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC

Benjamin P. Saylor

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

February 15th 2025

Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status

Benjamin P. Saylor

OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.

Related Content

Advertisement

February 19th 2025

FDA approves expanded access program to provide alternative source of BCG

Hannah Clarke

According to ImmunityBio, shipments of rBCG are set to begin immediately via the EAP.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

February 17th 2025

Anktiva under review in UK for BCG-unresponsive NMIBC with CIS

Hannah Clarke

Anktiva is also currently under review for the CIS indication in the EU.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

February 15th 2025

Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC

Benjamin P. Saylor

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

February 15th 2025

Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status

Benjamin P. Saylor

OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.